evolution cbd 3 in 1

Cbd Oil For Dogs 10 Things You Didn T Know Non Thc Medical Grade Cbd Oil Organic Type Of Cbd Oil For Multiple Sclerosis

To find the most current information, please enter your topic of interest into our search box.

Evolution 3 In 1 Cbd Oil How Many Drops Of Cbd Oil Should I Take 3mg Per Serving Drops

Can I Buy Hempworx Cbd Oil In Michigan May 2018 Over The Counter Cbd Oil Full Strenght How Many Miligrams Of Cbd Oil For Age 14 Cbd Oil For Dogs 10 Things You Didn T Know

Can I Buy Hempworx Cbd Oil In Michigan May 2018

Boy From Des Moines Iowa Cbd Oil And Seizures Can Cbd Tincture Oil Be Put In Drinking Water

Methods: Web-based real-time data collection techniques are combined with traditional patients’ diaries to capture a wide spectrum of outcomes associated with this innovative cannabis-based medication. After surpassing the recruitment threshold of 300 patients, an interim analysis was performed to determine whether the data collected to date align with those from MOVE 2-Germany and the largest phase III randomized controlled trial (RCT) of THC:CBD oromucosal spray.

Background: The prospective observational MObility ImproVEment (MOVE) 2 study is collecting real-life clinical outcomes data on patients with treatment-resistant multiple sclerosis (MS) spasticity treated with THC:CBD oromucosal spray in routine clinical practice. The MOVE 2 study has been ongoing in Italy, involving more than 30 MS centres across the country, since 2013.

Results: In the Italian cohort, THC:CBD oromucosal spray was added mainly to oral baclofen. Similar to MOVE 2-Germany, during 3 months’ observation, treatment discontinuations were limited and patients recorded meaningful improvements on the patient-based 0-10 numerical rating scale and physician-rated modified Ashworth scale at mean daily doses that were about one-third lower than those used in the RCT. Also, similar to MOVE 2-Germany, the proportion of patients reporting adverse events was about one-third of the rate recorded in the RCT.

Conclusions: While MOVE 2-Italy continues, this interim analysis has enabled us to better define the place in therapy of THC:CBD oromucosal spray within the context of daily management of our patients with MS spasticity.